Pilot Study on the Effects of Neuromuscular Taping in Parkinson's Disease Patients (NMT-PD)

IRCCS San Raffaele Roma

Status

Completed

Conditions

Parkinson Disease

Treatments

Device: Neuromuscular taping

Study type

Interventional

Funder types

Other

Identifiers

NCT03104049

RP 07/15

Details and patient eligibility

About

Parkinson's disease (PD) is a degenerative disorder characterized by a symptom triad consisting on: tremor, rigidity and bradykinesia . To these symptoms it is often added postural alteration that can stand in two different attitudes, such as the camptocormia and the syndrome of Pisa . Progressing in its evolution, PD becomes increasingly disabling, making it difficult or even impossible daily activities such as washing or dressing.The abnormal posture, with alteration of the limbs, the neck and trunk, is a recurring feature in PD, with a frequency of about 30%. Between 2% and 12.3% are more severe abnormalities such as camptocormia, the syndrome of Pisa and the anterocollis. Several studies disease plug in Neuromuscular Taping technique (NMT) among rehabilitative tools in degenerative neurological syndromes.

To the best of our knowledge, no applications were found in PD. Therefore, the current study was designed to evaluate quantitatively the effects of the NMT intervention on the trunk kinematics during standing position. More specifically, this study aims to compare the trunk kinematic variables of patients with PD who were treated with effective NMT versus those of the subjects who received only the pharmacological treatment.

Enrollment

46 patients

Sex

All

Ages

60 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Diagnosis of idiopathic PD by United Kingdom Brain Bank criteria
No other significant neurological or orthopedic problems
Age between 55 and 80 years
MDS-UPDRS item 3.13 Posture between mild and moderate (definite flexion, scoliosis or leaning to one side)
Patient able to walk independently or with minimal assistance for 10 meters
Medical treatment for Parkinson's Disease must be stable for at least two weeks prior to inclusion, and during the study. During the study, the dosage of anti-parkinsonian drug treatment should not change, if it is not deemed necessary by the investigator.

Exclusion criteria

Disability to understand instructions required by the study (Informed Consent Test of Comprehension)
primarily wheelchair bound
Skin abrasions
sensitive skin